Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer - Clifton, GT; Hale, D; Vreeland, TJ (Clin Cancer Research, 2020)